- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| XUANZHU BIOPHARMACEUTICAL Aktie jetzt für 0€ handeln | |||||
| 22.10. | XUANZHUBIO-B Phase III Clinical Study Data of Annerrazole Sodium for Reflux Esophagitis Presented at UEG Week 2026 | 2 | AASTOCKS | ||
| 21.10. | XUANZHUBIO-B (02575): VOLUNTARY ANNOUNCEMENT PHASE III CLINICAL STUDY DATA OF ANAPRAZOLE SODIUM FOR REFLUX ESOPHAGITIS PRESENTED AT UEG WEEK 2026PRESENTED ... | 2 | HKEx | ||
| 17.09. | XUANZHUBIO-B (02575): VOLUNTARY ANNOUNCEMENT UNUSUAL PRICE MOVEMENTS | 1 | HKEx | ||
| 16.09. | XUANZHUBIO-B (02575): 2025 ANNUAL REPORT - SUPPLEMENTAL INFORMATION | 2 | HKEx | ||
| 16.09. | XUANZHUBIO-B (02575): 2026 INTERIM REPORT | 1 | HKEx | ||
| 03.09. | XUANZHUBIO-B (02575): VOLUNTARY ANNOUNCEMENT COMMERCIAL COOPERATION WITH INNOBIC FOR BIREOCICLIB IN THE THAILAND MARKET | 3 | HKEx | ||
| 26.08. | XUANZHUBIO-B (02575): ANNOUNCEMENT OF INTERIM RESULTS FOR THE SIX MONTHS ENDED JUNE 30, 2026 | 1 | HKEx | ||
| 13.08. | XUANZHUBIO-B (02575): DATE OF BOARD MEETING | - | HKEx | ||
| 30.06. | XUANZHUBIO-B (02575): VOLUNTARY ANNOUNCEMENT NDA ACCEPTED BY NMPA FOR THE NEW INDICATION OF ANAPRAZOLE SODIUM FOR THE TREATMENT OF REFLUX ESOPHAGITIS | 3 | HKEx | ||
| 18.06. | XUANZHUBIO-B (02575): LIST OF DIRECTORS AND THEIR ROLE AND FUNCTION | - | HKEx | ||
| 18.06. | XUANZHUBIO-B (02575): ELECTION OF EMPLOYEE REPRESENTATIVE DIRECTOR | 1 | HKEx | ||
| 18.06. | XUANZHUBIO-B (02575): ARTICLES OF ASSOCIATION | 1 | HKEx | ||
| 18.06. | XUANZHUBIO-B (02575): POLL RESULTS OF THE 2025 ANNUAL GENERAL MEETING AND ABOLISHMENT OF THE SUPERVISORY COMMITTEE AND AMENDMENTS TO THE ARTICLES OF ASSOCIATION | - | HKEx | ||
| 27.05. | XUANZHUBIO-B (02575): FORM OF PROXY FOR THE ANNUAL GENERAL MEETING | 3 | HKEx | ||
| 27.05. | XUANZHUBIO-B (02575): NOTICE OF THE 2025 ANNUAL GENERAL MEETING | 1 | HKEx | ||
| 27.05. | XUANZHUBIO-B (02575): CIRCULAR FOR THE 2025 ANNUAL GENERAL MEETING | 1 | HKEx | ||
| 26.05. | XUANZHUBIO-B (02575): PROPOSED AMENDMENT TO THE ARTICLES OF ASSOCIATION, ABOLITION OF THE SUPERVISORY COMMITTEE AND CHANGE OF BOARD COMPOSITION | - | HKEx | ||
| 27.03. | XFRA NEW INSTRUMENTS AVAILABLE ON 27.03.2026 | 1.010 | Xetra Newsboard | The following instruments on XETRA do have their first trading 27.03.2026 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 27.03.2026
Aktien
1 SE0006887451 Corline Biomedical AB
2... ► Artikel lesen |
18 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 45,300 | +0,13 % | QIAGEN N.V.: QIAGEN Shareholders Overwhelmingly Approve Jonathan M. Pratt as Managing Director | QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that shareholders overwhelmingly approved the appointment of Jonathan M. Pratt as a Managing Director and member of the QIAGEN... ► Artikel lesen | |
| MBX BIOSCIENCES | 55,94 | 0,00 % | Citizens reiterates MBX Biosciences stock rating on GLP agonist data | ||
| ERASCA | 15,655 | -0,03 % | Erasca GAAP EPS of -$0.15 misses by $0.01 | ||
| TANGO THERAPEUTICS | 25,500 | 0,00 % | Jefferies raises Tango Therapeutics stock price target on trial data | ||
| VIR BIOTECHNOLOGY | 9,970 | +0,10 % | Vir Biotechnology: HDV-Daten lassen Aktie explodieren | Vir Biotechnology sorgt mit gleich zwei positiven Nachrichten im Bereich Hepatitis Delta für Aufsehen. Sowohl die ersten Ergebnisse der zulassungsrelevanten Phase-3-Studie als auch erweiterte Phase-2-Daten... ► Artikel lesen | |
| CG ONCOLOGY | 74,36 | -0,05 % | CG Oncology Inc.: CG Oncology Reports Second Quarter 2026 Financial Results and Provides Business Updates | PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy as an adjuvant therapy in intermediate-risk NMIBC anticipated in the near-termBLA completion for HR BCG-unresponsive NMIBC expected... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 14,140 | -0,07 % | Summit Therapeutics: Ivonescimab Plus Chemotherapy Demonstrates Overall Survival Superiority Compared to Durvalumab Plus Chemotherapy in First-Line Treatment of Patients with Advanced Biliary Tract Cancer in HARMONi-GI1 Study Conducted by Akeso in China | First Regimen to Achieve a Statistically Significant and Clinically Meaningful Overall Survival Benefit over an Anti-PD-(L)1 Antibody Combined with Chemotherapy in a Phase III Clinical Trial in... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 327,68 | -0,14 % | Praxis Precision Medicines stellt Markteinführungspläne für zwei Medikamentenkandidaten vor | ||
| RELAY THERAPEUTICS | 18,090 | 0,00 % | Relay Therapeutics, Inc.: Relay Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Updates | Selected zovegalisib plus atirmociclib as go-forward triplet regimen for 1L breast cancer; Phase 3 1L trial in endocrine- sensitive patients expected to initiate in early 2027, subject to regulatory... ► Artikel lesen | |
| ENLIVEN THERAPEUTICS | 48,810 | +0,02 % | Enliven Therapeutics, Inc.: Enliven Therapeutics Reports Third Quarter 2026 Financial Results and Provides a Business Update | Reached alignment with the FDA on the final design of the ENABLE-2 pivotal Phase 3 trial On track to initiate ENABLE-2 before year-end 2026 Strong balance sheet with $884 million in cash, cash equivalents... ► Artikel lesen | |
| ADMA BIOLOGICS | 13,690 | 0,00 % | Kehoe Law Firm, P.C.: ADMA Biologics (ADMA) Shareholder Alert: Kehoe Law Firm Investigates Potential Fiduciary Duty Breaches | Philadelphia, Pennsylvania--(Newsfile Corp. - August 5, 2026) - Kehoe Law Firm, P.C. is investigating whether certain officers and directors of ADMA Biologics, Inc. ("ADMA," "ADMA Biologics," or... ► Artikel lesen | |
| ABSCI | 8,440 | -0,12 % | Absci anticipates interim 13-week ABS-201 pattern hair loss data next month as it plans mid-2027 endometriosis Phase 2 start | ||
| PRIME MEDICINE | 4,270 | 0,00 % | Prime Medicine closes $143.7M public offering at $3.50/share | ||
| AMYLYX PHARMACEUTICALS | 30,300 | +0,03 % | Biotech Stocks At 52-Week Highs - Amylyx Pharmaceuticals +63% With Phase 3 Data, Vogenx +25%, Orchestra BioMed +19%, AtriCure, Charles River Laboratories | WASHINGTON (dpa-AFX) - The following biotech stocks reached a 52-week high on August 18, 2026, primarily driven by positive quarterly reports.Amylyx Pharmaceuticals Inc. (AMLX)Amylyx Pharmaceuticals... ► Artikel lesen | |
| PARABILIS MEDICINES | 28,430 | 0,00 % | Liberty Defense zahlt Darlehen über 2,45 Millionen US-Dollar an Parabilis vollständig zurück |
Das Unternehmen XUANZHU BIOPHARMACEUTICAL CO LTD kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell -6,38 % bei einem Aktienkurs von 0,924 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu XUANZHU BIOPHARMACEUTICAL CO LTD finden Sie auf Wallstreet Online.